The German company's only marketed product in the UK is Zydol, a painkiller used in the management of moderate to severe pain. But the company has ‘several' new products in the pipeline.
Last month it presented positive results on preclinical and early clinical studies of tapentadol, for pain-relief, at the fifth Congress of the European Federation of IASP Chapters in Istanbul.
Grünenthal has a licensing agreement for its co-development with Ortho-McNeil Pharmaceutical (Johnson & Johnson).
M&F reports to Grünenthal UK marketing manager Jon Daly, who said: ‘Chronic pain affects more than one in five adults across Europe and impacts all aspects of sufferers' lives.'
M&F healthcare practice head Bryony Box heads the account, which was won after a competitive pitch. It is handling trade, consumer and medical media relations.
The agency's most recent experience in the pain arena is with Cephalon's Actiq product.
Grünenthal was founded in Stolberg in 1946 and today has its HQ in Aachen.
The company's UK offices are in High Wycombe, Buckinghamshire.
